← All trials
NCT05776043
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2022
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 31, 2025
- First posted
- Mar 20, 2023
- Last posted
- Mar 20, 2023
- Enrollment
- 1364
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of WarsawLead sponsor
- Medical University of GdanskCollaborator
- Medical University of GrazCollaborator
- Medical University of ViennaCollaborator
- Poznan UniversityCollaborator
- Nicolaus Copernicus UniversityCollaborator
- Silesian University of MedicineCollaborator
- John Paul II Hospital, KrakowCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.